Baxter International Inc. $BAX Shares Purchased by Fiduciary Alliance LLC

Fiduciary Alliance LLC boosted its holdings in Baxter International Inc. (NYSE:BAX) by 42.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 131,958 shares of the medical instruments supplier’s stock after purchasing an additional 39,303 shares during the quarter. Fiduciary Alliance LLC’s holdings in Baxter International were worth $2,522,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC boosted its holdings in shares of Baxter International by 14.4% in the third quarter. EverSource Wealth Advisors LLC now owns 5,448 shares of the medical instruments supplier’s stock valued at $124,000 after acquiring an additional 686 shares during the period. Public Employees Retirement System of Ohio boosted its holdings in shares of Baxter International by 0.6% in the third quarter. Public Employees Retirement System of Ohio now owns 160,033 shares of the medical instruments supplier’s stock valued at $3,644,000 after acquiring an additional 993 shares during the period. Imprint Wealth LLC acquired a new stake in shares of Baxter International in the third quarter valued at approximately $27,000. CYBER HORNET ETFs LLC acquired a new stake in shares of Baxter International in the second quarter valued at approximately $40,000. Finally, MUFG Securities EMEA plc acquired a new stake in shares of Baxter International in the second quarter valued at approximately $46,000. 90.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Barclays cut their price target on Baxter International from $30.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. Citigroup cut their price target on Baxter International from $21.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, March 11th. Wall Street Zen cut Baxter International from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Evercore cut their price target on Baxter International from $23.00 to $22.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Finally, The Goldman Sachs Group cut their price target on Baxter International from $21.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, February 13th. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $19.80.

Trending Headlines about Baxter International

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Zacks raised its Q4 2026 EPS view to $0.61 (from $0.59), a modest upside for the late‑year quarter.
• Positive Sentiment: Zacks also nudged its FY2028 EPS estimate higher to $2.17 (from $2.12), signaling slightly improved longer‑term expectations.
• Neutral Sentiment: Baxter scheduled its Q1 2026 earnings call for Apr 30 — a key event for fresh revenue and margin details. Conference Call Announcement
• Negative Sentiment: Zacks cut multiple near‑term quarterly EPS estimates (Q1–Q3 2026 and Q1–Q3 2027) and lowered FY2026 to $1.88 (from $1.93) and FY2027 to $2.02 (from $2.08); the firm retains a “Hold” rating — pressure on near‑term growth expectations.
• Negative Sentiment: Evercore trimmed its price target on BAX to $22. Evercore Price Target Cut
• Negative Sentiment: Baxter’s FY2026 EPS guidance of $1.85–$2.05 sits slightly below the consensus midpoint (~$1.93); revenue guidance ~$11.2B–$11.4B is roughly in line but the lower EPS range reinforces investor caution.

Baxter International Trading Down 1.0%

Shares of BAX stock opened at $17.13 on Friday. Baxter International Inc. has a fifty-two week low of $15.73 and a fifty-two week high of $32.68. The stock has a market cap of $8.84 billion, a P/E ratio of -9.26, a P/E/G ratio of 1.22 and a beta of 0.62. The business has a fifty day simple moving average of $18.72 and a 200-day simple moving average of $19.64. The company has a quick ratio of 1.56, a current ratio of 2.31 and a debt-to-equity ratio of 1.55.

Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, February 12th. The medical instruments supplier reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.09). Baxter International had a negative net margin of 8.51% and a positive return on equity of 16.95%. The firm had revenue of $2.97 billion during the quarter, compared to analysts’ expectations of $2.82 billion. During the same quarter in the prior year, the business earned $0.58 EPS. The company’s quarterly revenue was up 8.0% compared to the same quarter last year. Baxter International has set its FY 2026 guidance at 1.850-2.050 EPS. On average, analysts forecast that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 1st. Stockholders of record on Friday, February 27th were given a $0.01 dividend. The ex-dividend date was Friday, February 27th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. Baxter International’s dividend payout ratio (DPR) is currently -2.16%.

Baxter International Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.